The Research Support Services Core provides administrative and budget management support for each Project and Core so that research goals may be achieved. Specific services are as follows: 1. Administrative and secretarial a) Organize the monthly scientific meeting of PPG investigators, including WebEx arrangements b) Coordinate the annual meeting of PPG investigators with Ext. Advisory Committee, and concomitant meeting of all NANT site principal investigators in Los Angeles. c) Assist with the Clinical Trials Agreements for the 15 NANT Consortium institutions and any industry sponsored NANT clinical trials d) Assist Project and Core Leaders with the preparation of grants and annual progress report to NCI e) Act as a liaison between CHLA, USC, and UCSF to facilitate subcontract agreements f) Assist Dr. Seeger with annual review of each Project and Core taking into account the External Scientific Review Committee written report, peer reviewed publications, presentations at scientific meetings, generation of phase I clinical protocols g) Provide administrative support to NANT Data Safety Monitoring Board(DSMB), Scientific Review Committee, and Study Management Committees, and assist with development of NANT SOP's;these are key components of Project 4 clinical trials consortium h) Maintain and upgrade NANT website ( as needed;website provides critical information tool for NANT clinical trials consortium i) Insure that all regulatory and compliance requirements are met for animal experimentation and human investigations j) Provide miscellaneous administrative support for Project 1- 4 2. Budget management a) Manage budget for all Projects and Cores b) Manage disbursements of funds for subcontracts with external institutions (USC, UCSF) and for capitation and correlative specimens to NANT consortium institutions c) Reimbursements for participants in Annual PPG and NANT meeting d) Honoraria for NANT DSMB members.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Children's Hospital of Los Angeles
Los Angeles
United States
Zip Code
Cho, Hwang Eui; Min, H Kang (2017) Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics. J Pharm Biomed Anal 132:117-124
Borriello, Lucia; Nakata, Rie; Sheard, Michael A et al. (2017) Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. Cancer Res 77:5142-5157
Erdreich-Epstein, Anat; Singh, Alok R; Joshi, Shweta et al. (2017) Association of high microvessel ?v?3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget 8:52193-52210
Tran, Hung C; Wan, Zesheng; Sheard, Michael A et al. (2017) TGF?R1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells. Clin Cancer Res 23:804-813
Villablanca, Judith G; Volchenboum, Samuel L; Cho, Hwangeui et al. (2016) A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer 63:1349-56
Vaughan, Lynsey; Clarke, Paul A; Barker, Karen et al. (2016) Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. Oncotarget 7:57525-57544
Borriello, Lucia; Seeger, Robert C; Asgharzadeh, Shahab et al. (2016) More than the genes, the tumor microenvironment in neuroblastoma. Cancer Lett 380:304-14
DuBois, Steven G; Marachelian, Araz; Fox, Elizabeth et al. (2016) Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol 34:1368-75
Trieu, Megan; DuBois, Steven G; Pon, Elizabeth et al. (2016) Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer 63:436-42
Challagundla, Kishore B; Wise, Petra M; Neviani, Paolo et al. (2015) Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Cancer Inst 107:

Showing the most recent 10 out of 140 publications